| 高丽,刘斌.血浆 D?二聚体检测在肺癌化疗评估中的临床意义[J].安徽医药,2020,24(6):1212-1214. |
| 血浆 D?二聚体检测在肺癌化疗评估中的临床意义 |
| Clinical significance of plasma D?dimer in evaluating the chemotherapeutic efficacy of lung cancer |
| |
| DOI：10.3969/j.issn.1009?6469.2020.06.039 |
| 中文关键词: 肺肿瘤 嘧啶二聚物 /诊断应用 抗肿瘤联合化疗方案 |
| 英文关键词: Lung neoplasms Pyrimidine dimers/diagnostic use Antineoplastic combined chemotherapy protocols |
| 基金项目: |
|
| 摘要点击次数: 1591 |
| 全文下载次数: 505 |
| 中文摘要: |
| 目的探讨血浆 D?二聚体在肺癌化疗评估中的意义。方法观察组选取 2017年 1月至 2019年 1月阜阳市人民医院 68例首次确诊的肺癌病人，所有病人经含铂双药一线方案进行化疗，同时另选取同医院 34例健康体检者为健康对照组。采用免疫比浊法测定肺癌组病人化疗前后血浆 D?二聚体的含量，以及体检者的血浆 D?二聚体含量。结果肺癌组化疗前及化疗后血浆 D?二聚体水平均高于对照组( P＜0.001)； Ⅳ期肺癌病人血浆 D?二聚体含量高于 Ⅲ期肺癌病人( P＜0.05)；小细胞肺癌(SCLC)与非小细胞肺癌( NSCLC)病人的血浆 D?二聚体含量差异无统计学意义( P＞0.05)；化疗后，疗效评估为有效组病人的血浆 D?二聚体含量 0.650(0.360，1.000)mg/L低于化疗前 0.810(0.360，1.680)mg/L(Z＝-2.989，P＝0.003)；进展组血浆 D?二聚体含量 0.830(0.550，2.130)mg/L高于化疗前 0.470(0.240，1.030)mg/L(Z＝-3.582，P＜0.001)。结论肺癌分期越晚、化疗效果越差、病情越重，血浆 D?二聚体水平越高，血浆 D?二聚体检测对于肺癌化疗疗效、病情变化的评估具有一定临床价值。 |
| 英文摘要: |
| Objective To investigate the significance of plasma D?dimer in evaluating the chemotherapeutic efficacy of lung cancer. Methods Sixty?eight patients with lung cancer confirmed for the first time in Fuyang People’s Hospital from January 2017 to Jan? uary 2019 were all treated by platinum?based chemotherapy.In addition，34 healthy people in the same hospital were selected asthe control group.Immunoturbidimetry was used to determine the level of plasma D?dimer in patients with lung cancer before and af?ter chemotherapy，and the level of plasma D?dimer in healthy controls.Results The levels of plasma D?dimer of the observation group were significantly higher than those of the control group(P＜0.001).The levels of plasma D?dimer in patients with stage IVlung cancer was significantly higher than that in patients with stage Ⅲ lung cancer(P＜0.05).There was no significant difference in the level of plasma D?dimer between small cell lung cancer(SCLC)patients and non?small cell lung cancer(NSCLC)patients(P＞0.05).After chemotherapy，the level of plasma D?dimer in patients with CR and PR was lower than that before chemotherapy［0.810(0.360，1.680)mg/L vs. 0.650(0.360，1.000)mg/L，Z＝-2.989，P＝0.003］； but the level of plasma D?dimer in patients with PD was higher than that before chemotherapy［0.470(0.240，1.030)mg/L vs. 0.830(0.550，2.130)mg/L，Z＝-3.582，P＜ 0.001］.Conclusion The later the stage of lung cancer，the poorer the chemotherapeutic efficacy，the worse the disease，the higherthe level of the plasma D?dimer.The detection of plasma D?dimer may be helpful to evaluate chemotherapeutic efficacy and changein patients’condition in patients of lung cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
